Special Issue "Predicting the Evolution of Neurological Diseases: The Role of Biomarkers in 2022 and Beyond"
Deadline for manuscript submissions: 31 December 2023 | Viewed by 9337
Interests: neurodegenerative diseases including Parkinson's disease, Huntington disease, other movement disorders, Alzheimer's disease; neuroimmune diseases including: multiple sclerosis, inflammatory neuropathies, myasthenia gravis
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Genetic Variants in Dopamine Receptors and Neurodegenerative Diseases
Topical Collection in International Journal of Molecular Sciences: Feature Papers in Molecular Genetics and Genomics
Special Issue in International Journal of Molecular Sciences: Genetics of Neurodegenerative Diseases 2.0
Special Issue in Biomedicines: Immune Landscape in Neurodegenerative Diseases
Special Issue in International Journal of Molecular Sciences: Genetics of Neurodegenerative Diseases 3.0
Special Issue in Journal of Clinical Medicine: Global Expert Views on Alzheimer's Disease, Dementia and Rehabilitation
Modern medicine is heading toward a personalized approach, and the definition of prognosis is a fundamental aspect of this strategy. The ability to predict disease evolution allows allocating the right therapy to the right patient, but also preparing the patient and the caregiver for the challenges that they will have to face. There are still several neurological conditions lacking a disease-modifying therapy, but this is expected to change in the near future, thus opening the way to a new era of disease management.
According to the World Health Organization (WHO), a biomarker is “any substance, structure, or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease”.
In this Special Issue, I would like to invite authors to submit studies focusing on prognostic biomarkers of neurological diseases. Authors are welcome to cover all areas of clinical neurology, including, but not limited to neurodegenerative diseases, neuroimmune/neuroinflammatory diseases, cerebrovascular diseases, brain tumors, and neuromuscular diseases.
Dr. Cristoforo Comi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Parkinson’s disease
- Alzheimer’s disease
- cerebrovascular disease
- multiple sclerosis
- amyotrophic lateral sclerosis
- disease progression